Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.

Abstract:

:The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, and to determine the potential clinical implications of early kinetics of mixed chimerism, we have investigated 66 allogeneic stem cell transplantations (SCTs) in 58 pediatric patients suffering from different types of leukemia (n = 44) or non-malignant hematologic disorders (n = 14) by close molecular monitoring during the first days and weeks after transplantation. Patient- and donor-derived hematopoiesis were assessed at 1- to 3-day intervals in peripheral blood samples by PCR analysis of highly polymorphic microsatellite loci (STR-PCR). Detection of an increasing, and ultimately dominant donor-specific allelic pattern, which we defined as molecular engraftment, preceded hematologic engraftment by a median of 7 days (range 1-17 days) in all patients investigated. PCR analyses during the first days after transplantation facilitated detection of molecular engraftment according to the above definition by day +14 (range day +2 to day +14), thus permitting prediction of successful engraftment (upper limit of the two-sided confidence interval po = 6%) while the peripheral leukocyte counts were mostly below 200/microl. In three cases, however, the criteria for molecular engraftment were not fulfilled by day +14. These patients also failed to show hematologic engraftment, and required a second transplantation. Close monitoring by STR-PCR showed that graft rejection and autologous recovery can occur early and with very rapid dynamics. Molecular analysis of specific leukocyte subsets isolated by flow-sorting enabled sensitive assessment of changes in the pattern of chimerism which had escaped detection in assays using whole white blood cell (WBC) samples. This approach facilitated the identification of expanding or decreasing recipient cells, and permitted early detection of impending rejection or relapse. Moreover, monitoring of the dynamics of chimerism allowed rapid assessment of the response to therapy. Our observations provide support for the concept of initiating genotype analyses early after SCT and monitoring at rather short intervals to permit timely evaluation of clinically relevant processes, and to provide a basis for early implementation of treatment.

journal_name

Leukemia

journal_title

Leukemia

authors

Dubovsky J,Daxberger H,Fritsch G,Printz D,Peters C,Matthes S,Gadner H,Lion T,Muller-Bérat N

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

2059, 2060-9

issue

12

eissn

0887-6924

issn

1476-5551

journal_volume

13

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Determination of clonality in patients who present with diagnostic dilemmas: a laboratory experience and review of the literature.

    abstract::Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400678

    authors: Rockman SP

    更新日期:1997-06-01 00:00:00

  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract::To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403010

    authors: Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期:2003-08-01 00:00:00

  • Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

    abstract::Alterations in the FLT3 gene, including internal tandem duplications (ITDs) and D835 mutations occur frequently in acute myelogenous leukemia. We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA pro...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402723

    authors: Noguera NI,Breccia M,Divona M,Diverio D,Costa V,De Santis S,Avvisati G,Pinazzi MB,Petti MC,Mandelli F,Lo Coco F

    更新日期:2002-11-01 00:00:00

  • Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells.

    abstract::Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in g...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.273

    authors: Malcherek G,Jin N,Hückelhoven AG,Mani J,Wang L,Gern U,Diehlmann A,Wuchter P,Schmitt A,Chen B,Ho AD,Schmitt M

    更新日期:2014-12-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract::The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.168

    authors: Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期:2009-11-01 00:00:00

  • A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

    abstract::All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0892-z

    authors: Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

    更新日期:2020-06-19 00:00:00

  • Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.

    abstract::Twenty patients with myelodysplastic syndromes were treated with daily subcutaneous injections of interferon alpha 2a, at the initial dose of 3 x 10(6) U/m2. Hemogram, chemistry profile, natural killer (NK) cell activity and lymphokine-activated killer (LAK) cell cytotoxicity were monitored serially. Bone marrow with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Nand S,Ellis T,Messmore H,Fisher SG,Gaynor E,Fisher RI

    更新日期:1992-03-01 00:00:00

  • Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.

    abstract::MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403833

    authors: Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

    更新日期:2005-08-01 00:00:00

  • Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.

    abstract::Four randomized prospective studies on interferon alpha (IFN) in CML report varying degrees of prolongation of the chronic phase of CML and of survival as compared to conventional therapies. There is agreement that IFN prolongs survival as compared to standard busulfan. There is disagreement, however, as to which degr...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Hehlmann R,Willer A,Heimpel H,Hasford J,Kolb HJ,Pralle H,Hossfeld DK,Queisser W,Löffler H,Hochhaus A,Tobler A,Lengfelder E,Berger U,Leib-Mösch C

    更新日期:1997-04-01 00:00:00

  • Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns.

    abstract::Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assem...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Felix CA,Poplack DG

    更新日期:1991-12-01 00:00:00

  • In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.

    abstract::Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metabolite of fludarabine phosphate, fludarabine (9-beta-D-arabinofuranosyl-2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401684

    authors: Kano Y,Akutsu M,Tsunoda S,Suzuki K,Ichikawa A,Furukawa Y,Bai L,Kon K

    更新日期:2000-03-01 00:00:00

  • Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.

    abstract::This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Frassoni F,Carella AM

    更新日期:1996-06-01 00:00:00

  • Donor leukemia following allogeneic bone marrow transplantation.

    abstract::Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. Leukemic relapse occurs in recipient cells in the majority of cases, but the paucity of donor cell leukemias may reflect the sensitivity of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Mc Cann SR,Lawler M,Gardiner N,O'Riordan J,Humphries P,De Arce M

    更新日期:1994-04-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract::We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400768

    authors: Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期:1997-09-01 00:00:00

  • Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

    abstract::Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Tran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0527-4

    authors: Gilleece MH,Labopin M,Savani BN,Yakoub-Agha I,Socié G,Gedde-Dahl T,Blaise D,Byrne JL,Craddock C,Cornelissen JJ,Arcese W,Forcade E,Crawley C,Polge E,Mohty M,Nagler A

    更新日期:2020-01-01 00:00:00

  • Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells.

    abstract::Hematopoietic stem/progenitor cells (HSC/P) reside in the bone marrow in distinct anatomic locations (niches) to receive growth, survival and differentiation signals. HSC/P localization and migration between niches depend on cell-cell and cell-matrix interactions, which result from the cooperation of cytokines, chemok...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404769

    authors: Glodek AM,Le Y,Dykxhoorn DM,Park SY,Mostoslavsky G,Mulligan R,Lieberman J,Beggs HE,Honczarenko M,Silberstein LE

    更新日期:2007-08-01 00:00:00

  • Quantitative analysis of Op18 phosphorylation in childhood acute leukemia.

    abstract::Oncoprotein 18 (Op18) is a major cystolic phosphoprotein constituent of leukemia cells. There is cumulative evidence that suggests a role for Op18 in integrating signals from diverse pathways involved in cell growth. Op18 phosphorylation is induced with proliferation in a variety of cell types, and is essential for ce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400792

    authors: Melhem R,Hailat N,Kuick R,Hanash SM

    更新日期:1997-10-01 00:00:00

  • Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes.

    abstract::The MDM2 gene is a gene whose product binds to p53 and regulates its function. Amplification of MDM2 has been found in human sarcomas, where it leads to inactivation of p53. In 64 cases of generally advanced myelodysplastic syndromes, we found no amplification or rearrangement of MDM2 gene by Southern analysis. MDM2 R...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Preudhomme C,Quesnel B,Vachee A,Lepelley P,Collyn-D'Hooghe M,Wattel E,Fenaux P

    更新日期:1993-08-01 00:00:00

  • The human lysozyme gene undergoes stepwise demethylation during phagocyte maturation.

    abstract::The lysozyme (LZM) gene provides a very useful model for studies of phagocyte maturation, because its protein synthesis is increased during myelopoiesis and thus most abundant in terminally differentiated and activated phagoyctes. LZM gene expression and DNA methylation were examined in various normal and transformed ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400693

    authors: Lübbert M,Henschler R,Kreutz M,Andreesen R,Mertelsmann R,Herrmann F

    更新日期:1997-07-01 00:00:00

  • Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.

    abstract::Interleukin-2 (IL-2) is a growth factor which upon binding to high-affinity receptors (IL-2Ralphabetagamma) triggers mitogenesis in T cells. IL-2Ralpha expression is restricted to T cells which have recently encountered antigen, and in healthy individuals the majority (>95%) of peripheral T cells are IL-2Ralpha negati...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402093

    authors: Eriksen KW,Kaltoft K,Mikkelsen G,Nielsen M,Zhang Q,Geisler C,Nissen MH,Röpke C,Wasik MA,Odum N

    更新日期:2001-05-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract::Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.147

    authors: Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期:2016-11-01 00:00:00

  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract::Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.78

    authors: Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期:2014-09-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0334-3

    authors: Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期:2019-06-01 00:00:00

  • Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

    abstract::Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.328

    authors: Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

    更新日期:2016-04-01 00:00:00

  • Dissecting the pathways to death.

    abstract::This report summarizes recent findings in the field of basic and translational apoptosis research which were presented at the 1st Conference on 'Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention' organized by the European School of Hematology and the University of Texas MD Anderson Cancer Cent...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401940

    authors: Daniel PT

    更新日期:2000-12-01 00:00:00

  • Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.

    abstract::Tumor-infiltrating T-lymphocytes (T-TIL) are putative mediators of tumor containment that exhibit unique specificity for autologous tumor cells. The magnitude of T-TIL response in biopsy specimens from patients with B-cell lymphoma has been suggested as an independent predictor of clinical outcome. Since recognition o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: List AF,Spier CM,Miller TP,Grogan TM

    更新日期:1993-03-01 00:00:00

  • Stromal cell-mediated transcriptional regulation of the CD13/aminopeptidase N gene in leukemic cells.

    abstract::CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

    更新日期:1995-09-01 00:00:00

  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

    abstract::Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41375-020-0718-z

    authors: Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

    更新日期:2020-07-01 00:00:00

  • Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

    abstract::Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404734

    authors: Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

    更新日期:2007-07-01 00:00:00

  • Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

    abstract::In cell and animal models, telomere erosion promotes chromosomal instability via breakage-fusion-bridge cycles, contributing to the early stages of tumorigenesis. However, evidence involving short telomeres in cancer development in humans is scarce, epidemiological and indirect. Here we directly implicate telomere sho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.272

    authors: Calado RT,Cooper JN,Padilla-Nash HM,Sloand EM,Wu CO,Scheinberg P,Ried T,Young NS

    更新日期:2012-04-01 00:00:00